This compound also promotes the constitutive phosphorylation of ERK2 via ROS and MDM2-mediated ubiquitination and degradation of mutp53, suggesting a combinational therapy of this compound and ROS-inducing agents to treat mutp53 human cancers [78]. Here, MDM2 is linked to cancer.